Insights On Drug Discovery

  1. Solving The Inhalation Puzzle: A CDMO's Guide To Dry Powder Development 7/9/2025

    Gain guidance on the choice of formulation, excipients, and the micronization technologies offered by CDMOs, and learn about current encapsulation technologies for inhaled products.

  2. New Approaches To Tailored Release Profiles 7/7/2025

    Tailored drug release is evolving from formulation tactic to precision therapy strategy, optimizing timing, site, and rate of delivery for improved patient outcomes.

  3. Securing A Treatment Through Grit And Collaboration 7/3/2025

    Discover how one family defied the odds — bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

  4. Creating Your ADC Supply Chain 6/26/2025

    Antibody-drug conjugates (ADCs) are on the rise. Supply chains to serve ADC developers can be complicated, and spread out. Reza Oliyai has some key interpretations of how these therapies can string together optimal - and at times far-reaching - supply chains.

  5. Your CDMO Knows A Lot - Are You Listening? 6/26/2025

    Our three experienced panelists weigh in on how sponsors should take advantage of what CDMOs know from experience in quality, regulatory, and other aspects of development and processing.

  6. CDMO SOWs Must (Re-)Align With New Project Realities 6/26/2025

    Decades of experience in cell and gene therapy outsourcing have taught Donna Rill, Chief Technology Officer, Triumvira Immunologics, that the key to success is ensuring CDMOs and sponsors understand the need to continuously align SOWs with the variances as projects move forward.

  7. Here's Where CDMOs Improve For Cell And Gene Therapy Customers? 6/26/2025

    Donna Rill, Chief Technology Officer, Triumvira Immunologics, has advice for CDMOs to improve their service to CGT customers, and conversely, where drug developers can improve as well.

  8. Are You Asking For Unrealistic Flexibility At Your CDMO? 6/26/2025

    Our experienced Outsourced Pharma Live panel considers what is doable, and what is not, when it comes to the demands some sponsors put on CDMOs.

  9. Blood Brain Permeability And CNS Bioavailability Of Targeted Protein Degraders 6/20/2025

    Evidence suggests that the inherent flexibility of Targeted Protein Degraders (TPDs) can be leveraged to optimize key parameters such as solubility, permeability, and oral bioavailability.

  10. Experimental Pain Models — SNL Model Of Neuropathic Pain 6/20/2025

    Explore how a validated Spinal Nerve Ligation (SNL) model enables effective preclinical evaluation of novel analgesics for neuropathic pain.